drugset / Trial / NCT01803087
Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients
RandomizedCrossoverOpen-labelTreatment
Summary
This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products; this will be additionally compared to the systemic exposure in adults without the spacer device.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Formoterol | Other / unclassified | 24 ug | Inhaled |
| Comparator | beclomethasone dipropionate | Other / unclassified | 400 ug | Inhaled |